Johnson & Johnson Q3 Earnings: Can Revenue Growth Outshine Profit Pressures and New Acquisitions?

Johnson & Johnson (JNJ) is scheduled to release its third-quarter earnings on Tuesday morning, with analysts anticipating an increase in revenue but a decline in profits compared to the same period last year.

This quarter marks one year since the company finalized the spinoff of its consumer health division, establishing Kenvue as a separate public entity. Kenvue now manages popular household brands such as Tylenol and Band-Aid, a move that allowed Johnson & Johnson to streamline its focus on pharmaceuticals and medical devices.

Analysts forecast that the company will report $22.21 billion in revenue for the quarter, a 4% increase from the $21.35 billion reported in the same period last year, according to data from Visible Alpha. However, net income is expected to fall to $4.07 billion, down from $4.31 billion in the third quarter of 2022. It is worth noting that Johnson & Johnson recorded a $21 billion one-time gain last year from discontinuing operations linked to the consumer health business, which contributed to its separation from the core business.

The company has been actively adjusting its full-year outlook throughout 2023, and management has indicated that another revision is forthcoming. In the first quarter, the company narrowed its sales and profit expectations, while in the second quarter, it raised its sales forecast but lowered profit projections, largely due to acquisitions. Last week, Johnson & Johnson confirmed it would update its guidance again, factoring in its recent acquisition of V-Wave, a developer of heart failure treatments. The deal, which was announced in August and valued at up to $1.7 billion, reflects the company’s focus on expanding its portfolio of innovative medical treatments.

Johnson & Johnson's acquisition of V-Wave is part of a broader strategy to enhance its drug development pipeline, which spans multiple therapeutic areas, including cancer treatment and cardiovascular health. With approximately 100 drugs at various stages of development—ranging from clinical trials to regulatory submissions—the company continues to position itself as a leader in the pharmaceutical and medical device sectors.

Despite the recent developments, Johnson & Johnson's stock has shown little movement, closing at $160.51 on Thursday. Year-to-date, the shares have gained just over 2%. Investors will be watching closely for any surprises in the earnings report and updated guidance, as these factors could shape the stock’s trajectory in the near term.